[
  {
    "ts": "2026-02-19T08:30:00+00:00",
    "headline": "Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Amyotrophic Lateral Sclerosis Therapeutics Market size & share revenue was valued at approximately USD 812 Million in 2024 and is expected to reach USD 1053 Million in 2025 and is expected to reach around USD 1964 Million by 2035, at a CAGR of 11.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Mitsub",
    "url": "https://finance.yahoo.com/news/global-amyotrophic-lateral-sclerosis-therapeutics-083000500.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "ab9a3506-f0d8-35a8-a4d6-24a3e0b42c27",
      "content": {
        "id": "ab9a3506-f0d8-35a8-a4d6-24a3e0b42c27",
        "contentType": "STORY",
        "title": "Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
        "description": "",
        "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Amyotrophic Lateral Sclerosis Therapeutics Market size & share revenue was valued at approximately USD 812 Million in 2024 and is expected to reach USD 1053 Million in 2025 and is expected to reach around USD 1964 Million by 2035, at a CAGR of 11.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Mitsub",
        "pubDate": "2026-02-19T08:30:00Z",
        "displayTime": "2026-02-19T08:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891",
          "originalWidth": 2514,
          "originalHeight": 1281,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CrZC42kgw2SjdY2CY6ucw--~B/aD0xMjgxO3c9MjUxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 2514,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/91DUI4_rVm8Et9pJYV6I4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/global-amyotrophic-lateral-sclerosis-therapeutics-083000500.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/global-amyotrophic-lateral-sclerosis-therapeutics-083000500.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABSCF"
            },
            {
              "symbol": "MNOV"
            },
            {
              "symbol": "TAK"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SUNPHARMA.NS"
            },
            {
              "symbol": "BHVN"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "IONS"
            },
            {
              "symbol": "AMLX"
            },
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "BCLI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T15:22:18+00:00",
    "headline": "Assessing Biogen (BIIB) Valuation As Shares Gain 18.1% In 30 Days And 42% Over One Year",
    "summary": "Key recent performance and business profile Biogen (BIIB) has moved quietly higher, with the share price showing a 0.8% decline over the last day but gains of 1.5% over the past week and 18.1% over the past month. Over the past 3 months, the stock is up 15.4%, while the year-to-date move sits at 9.2%, and the 1-year total return stands at 42%. Longer term, total returns over 3 and 5 years are negative, at 28.8% and 31.3% declines respectively. The company reports annual revenue of US$9.89b...",
    "url": "https://finance.yahoo.com/news/assessing-biogen-biib-valuation-shares-152218999.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "329d650d-2224-3458-a250-0a33bff45f74",
      "content": {
        "id": "329d650d-2224-3458-a250-0a33bff45f74",
        "contentType": "STORY",
        "title": "Assessing Biogen (BIIB) Valuation As Shares Gain 18.1% In 30 Days And 42% Over One Year",
        "description": "",
        "summary": "Key recent performance and business profile Biogen (BIIB) has moved quietly higher, with the share price showing a 0.8% decline over the last day but gains of 1.5% over the past week and 18.1% over the past month. Over the past 3 months, the stock is up 15.4%, while the year-to-date move sits at 9.2%, and the 1-year total return stands at 42%. Longer term, total returns over 3 and 5 years are negative, at 28.8% and 31.3% declines respectively. The company reports annual revenue of US$9.89b...",
        "pubDate": "2026-02-19T15:22:18Z",
        "displayTime": "2026-02-19T15:22:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-biogen-biib-valuation-shares-152218999.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-biogen-biib-valuation-shares-152218999.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T17:13:27+00:00",
    "headline": "New Biogen Chair Freire May Recast Partnerships And Capital Priorities",
    "summary": "Biogen (NasdaqGS:BIIB) has appointed Dr. Maria C. Freire as Chair of its Board of Directors. Dr. Freire brings experience in biomedical research, drug development, and public private partnerships. The appointment marks a transition in board leadership that could influence Biogen’s future direction. Biogen, known for its focus on neuroscience and other serious neurological conditions, is operating in a sector where drug development cycles, regulation, and partnerships with research...",
    "url": "https://finance.yahoo.com/news/biogen-chair-freire-may-recast-171327597.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f1962c39-3be1-36cd-8bec-11312855cfba",
      "content": {
        "id": "f1962c39-3be1-36cd-8bec-11312855cfba",
        "contentType": "STORY",
        "title": "New Biogen Chair Freire May Recast Partnerships And Capital Priorities",
        "description": "",
        "summary": "Biogen (NasdaqGS:BIIB) has appointed Dr. Maria C. Freire as Chair of its Board of Directors. Dr. Freire brings experience in biomedical research, drug development, and public private partnerships. The appointment marks a transition in board leadership that could influence Biogen’s future direction. Biogen, known for its focus on neuroscience and other serious neurological conditions, is operating in a sector where drug development cycles, regulation, and partnerships with research...",
        "pubDate": "2026-02-19T17:13:27Z",
        "displayTime": "2026-02-19T17:13:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-chair-freire-may-recast-171327597.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-chair-freire-may-recast-171327597.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T04:37:46+00:00",
    "headline": "3 Value Stocks Walking a Fine Line",
    "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
    "url": "https://finance.yahoo.com/news/3-value-stocks-walking-fine-043746736.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "51a83dfb-30ab-3136-90e8-3204a044a6b2",
      "content": {
        "id": "51a83dfb-30ab-3136-90e8-3204a044a6b2",
        "contentType": "STORY",
        "title": "3 Value Stocks Walking a Fine Line",
        "description": "",
        "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
        "pubDate": "2026-02-19T04:37:46Z",
        "displayTime": "2026-02-19T04:37:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/f6ff65b5bedc64751bae04a793e2e34b",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PANL Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OH8BSJf40P3ooMlWbAyiPA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/f6ff65b5bedc64751bae04a793e2e34b.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UFStqBAKd67OqYLJv3n3KA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/f6ff65b5bedc64751bae04a793e2e34b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-value-stocks-walking-fine-043746736.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-value-stocks-walking-fine-043746736.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PANL"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "WEX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]